Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Clinical Centers (Collaborative U01)

 

The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to continue follow-up of the Diabetes Prevention Program Outcomes Study (DPPOS) cohort through a collaborative cooperative agreement. The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial examining the efficacy of treatments to prevent or delay the development of type 2 diabetes in a population at high risk. The DPP demonstrated that either lifestyle change or the drug metformin could reduce the development of type 2 diabetes by 58% and 31%, respectively, compared with placebo. Following the end of DPP, the DPP cohort was enrolled in the DPPOS to determine the long-term effects of the DPP interventions on further diabetes development and microvascular complications. The primary purpose of this FOA is to support the DPPOS clinical centers to continue follow-up of the DPPOS cohort to examine the effectiveness of early metformin treatment on the development of cardiovascular disease and cancer. RFA-DK-15-505 will support continuation of the DPPOS Biostatistics Research Center.

Deleted 05/10/2015 (Archived.) RFA-DK-15-503 Agency: Department of Health and Human Services
Office: National Institutes of Health Cooperative Agreement 21 Other Eligible Applicants include the following: This FOA is limited to the current awardees of the Diabetes Prevention Program Outcomes Study (DPPOS) Clinical Centers. 04/09/2015 This program does not have cost sharing or matching requirements. NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-15-503.html FBOWebmaster@OD.NIH.GOV $10,000,000.00